Eli Lilly and Company said on Wednesday that it would reduce the price of its most commonly prescribed insulins and expand a program that caps monthly out-of-pocket costs for patients at $35 or less.
It said the company was taking the action to “help Americans who may have difficulty navigating a complex health care system that may keep them from getting affordable insulin.”
Insulin, a lifesaving drug that is usually taken daily, has grown increasingly expensive in recent years, and many diabetes patients ration their medicines or discontinue them because of the cost. More than 30 million Americans live with diabetes.
It comes after years of mounting criticism from Americans who have said the drug should be more accessible. The criticism led to lawsuits and legislation.
Related Coverage
AllSides Picks
Headline Roundup
ACA Open Enrollment Begins: Can Americans Afford Rising Health Insurance Costs?
November 1st, 2026
Announcement
Why AllSides Uses the Term ‘Assisted Dying’ and Not ‘Assisted Suicide’
AllSides Staff
October 31st, 2026
Bias
Media Bias Alert: Are OB-GYNs Fleeing Idaho Because of Abortion Bans?
Emily Allen
October 23rd, 2026
Red Blue Translator
Big Pharma
More News about Healthcare
News from the Left
News from the Center
News from the Right
Just The News